Healthcare Industry News: CytoGam
News Release - December 18, 2006
ZLB Behring Completes Purchase of CytoGam(R) Immunoglobulin Therapy From MedImmuneKING OF PRUSSIA, Pa.--(HSMN NewsFeed)--ZLB Behring, a global leader in the plasma protein biotherapeutics industry and subsidiary of CSL Ltd. (ASX: CSL ), today announced it has completed its purchase of CytoGam® (cytomegalovirus immunoglobulin intravenous (human)) and related assets from MedImmune, Inc. CytoGam is an intravenous immunoglobulin enriched in antibodies against cytomegalovirus (CMV), which is indicated for preventing CMV disease associated with transplantation of the kidney, lung, liver, pancreas and heart. CMV is the most common cause of life-threatening infection occurring in solid organ transplants.
ZLB Behring paid U.S. $120 million in cash, $70 million of which is subject to achievement of sales milestones. ZLB Behring manufactures immunoglobulins and other plasma-derived therapies, and markets them in more than 100 countries.
The acquisition includes CytoGam and related assets, including trademarks, manufacturing contracts and government authorizations associated with the product.
CytoGam is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart. In transplants of these organs other than kidney from CMV seropositive donors into seronegative recipients, prophylactic CMV-IVIg should be considered in combination with ganciclovir.
CytoGam is made from human plasma and, like other plasma products, carries the possibility for transmission of blood-borne viral agents. CytoGam should not be used in individuals with a history of a prior severe reaction to CytoGam or other human immunoglobulins. Immunoglobulin Intravenous (Human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. CytoGam contains sucrose as a stabilizer. In patients predisposed to acute renal failure, IVIg products should be administered at the minimum concentrations available and the minimum rate of infusion practical. Severe reactions such as angioneurotic edema and anaphylactic shock, although not observed during clinical trials, are a possibility. Minor reactions such as flushing, chills, muscle cramps, back pain, fever, nausea, vomiting, arthralgia, and wheezing were the most frequent adverse reactions observed during clinical trials. For more information, please download a package insert at http://www.zlbbehring.com/docs/666/202/cytogam_pi.pdf
About ZLB Behring
ZLB Behring is a global leader in the plasma protein biotherapeutics industry. Dedicated to improving the quality of life for patients throughout the world, ZLB Behring provides safe and effective plasma-derived and recombinant products and offers patients a wide range of related services. The company's broad portfolio of life-saving therapeutics is used in the treatment of individuals with hemophilia, von Willebrand Disease and other bleeding disorders, immune deficiency disorders, and inherited emphysema; for the prevention of hemolytic diseases for the newborn; in cardiac surgery patients; and in shock and burn victims. Additionally, ZLB Behring operates one of the world's largest, fully owned plasma collection networks. ZLB Behring is a subsidiary of CSL Limited, a biopharmaceutical company, which operates worldwide from its headquarters in Melbourne, Australia. For more information, please visit www.ZLBBehring.com.
Source: ZLB Behring
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.